Europe
Promore Pharma AB announced that the company has entered into an agreement with ABG Sundal Collier ASA whereby ABGSC will act as liquidity provider for the Promore Pharma share starting 21 October.
An easy-to-use electrode set can assess sleep bruxism severity as well as a conventional polysomnography, a new study from the University of Eastern Finland shows
Several events relevant to UK pharma have occurred recently. Here’s a look.
When it comes to specific attributes, having the opportunity to do interesting and meaningful work, securing a competitive salary and having access to quality health benefits were the most important. Here are some differences when it comes to generational priorities.
The approval is based on the Phase III UNIFI study that showed that after eight weeks of taking a single intravenous dose of Stelara, patients saw “clinical remission in a significantly greater proportion of UC patients.”
Thanks to a new regulatory win, AstraZeneca’s Farxiga can now be used to reduce the risk of hospitalization for heart failure in type 2 diabetes patients with cardiovascular disease and with certain risk factors.
The trial met its co-primary endpoints, showing statistically significant and clinically meaningful improvements in overall survival and progression-free survival compared to standard-of-care, Bayer’s Nexavar.
Last week was busy for clinical trial news. Here’s a look.
Janssen Pharmaceutical of Johnson & Johnson released new long-term data from the open-label period of its Phase III VOYAGE 1 clinical trial.
Promore Pharma AB announced the composition of the Nomination Committee for the Annual General Meeting 2020, which will be held on Tuesday 26 May 2020.
PRESS RELEASES